cagrisema cagrilintide semaglutide phase 3 results 2024 2025 obesity Presenters to provide first look at data from REIMAGINE trials of cagrilintide/semaglutide for type 2 diabetes management Novo Nordisk's stock drops despite
Novo Nordisk's stock drops despite CagriSema hitting goal of Phase III trial Clinical Trials Arena Novo Nordisk's next gen obesity drug CagriSema trial results disappoint investors Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints Reuters Novo's Phase 3 CagriSema results disappoint analysts, sending stock tumbling MM+M Medical Marketing and Media
Pay in 4 interest-free payments of $5.71 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5



